A vaccine for Ebola which is deadly disease, but with a very limited geographical spread outside the first world i.e. Central Africa, was developed at breakneck speed with no reference to profitability whatsoeverYes, they are more than willing to develop vaccines that have a huge market potential and also why we do not have vaccines for deadly diseases that have limited markets or markets unable to pay for them hence are not profitable to develop and market. The Covid 19 is a good example of that. I doubt anyone really thinks that Covid 19 vaccines would have been developed and approved quickly if Covid was only a problem in underdeveloped countries and not first world countries. Strictly speaking there is very little that is humanitarian about big Pharma.
Bob
In the developed world for sure but for billions around the rest of the world it's not a matter of choice, there simply is not any for them.One of the contributing factors is a significant minority of people refusing the vaccine.
To depict the US as an isolated angel of mercy is unfortunately factually incorrect:The US has lead the way in lifting IPR on vaccines to enable third world countries to produce their own versions of the vaccine formula for their own market.
European pharmaceutical companies have made in excess of 25 billion euros in Profits out of the vaccine, their justification in this level of profit is that they have saved Europe a great deal of money.
Ebola has been around since 1976 but the 2014 - 2016 massive outbreak in Africa lit the fire to get a vaccine out into the field. The fear that this massive outbreak could spread to the rest of the world no doubt had something to do with the hasty development. One of the Ebola vaccines was developed in a Canadian government lab in Winnipeg Manitoba. The lab is funded by tax payer money iirc. I don't think waiting from 1976 to 2014 - 16 to get excited enough about an Ebola outbreak to get a vaccine out is exactly what I would call doing so at breakneck speed.A vaccine for Ebola which is deadly disease, but with a very limited geographical spread outside the first world i.e. Central Africa, was developed at breakneck speed with no reference to profitability whatsoever
Thanks for pointing out the situation with the IP owners of the mRNA vaccines.Not all pharmaceutical companies are big pharma. The IP owners for the mRNA vaccines each have ONE product commercialized, which is their respective mRNA vaccine. You are asking them to literally give up their only source of business. This one product enables them to stabilize and have a future and continue R&D investment into other products.
That said, I fully agree that in some cases drug prices are ridiculously high. The UK and European regulatory authorities actually do a reasonable job at managing pricing. The US is the worst ... seriously, THE F_CKING WORST. You can allow companies to profit without letting them profiteer, which is what the US effectively allows. Getting off-topic from vaccines, but look at what Viatris / Mylan is able to charge for EpiPen in the US versus Europe!